Retatrutide is not approved. Two trial records are recruiting.
A current registry tracker for retatrutide trial locations, enrollment status, active studies, expanded access, and the difference between an overall Recruiting label and an open local site.
Two records are recruiting overall. Neither is a simple open-enrollment route for obesity treatment.
ClinicalTrials.gov returned 34 intervention-search matches in the current snapshot: 20 Completed, 11 Active, not recruiting, 2 Recruiting, and 1 Available expanded-access record.
The two recruiting records have different sponsors, conditions, designs, and countries. SYNERGY-Outcomes is a multiple-agent MASLD master protocol. The separate China study is sponsored by Hudson Biotech and uses the LY3437943 development code. Together they retain 564 listed locations, while 450 individual site observations are currently marked Recruiting.
The Lilly obesity and chronic-low-back-pain study changed to Active, not recruiting before this release. It is therefore shown in the closed-to-new-enrollment table, not as a recruiting route.
Run the live ClinicalTrials.gov search →Read the study before the location list.
Overall status can change after this snapshot. Every card links to the live registry record, where the study team controls eligibility and current contact information.
SYNERGY-Outcomes master protocol in adults with metabolic dysfunction-associated steatotic liver disease
A multiple-agent master protocol that lists both retatrutide and tirzepatide interventions. The location ledger is not a retatrutide-arm assignment list and does not mean every site is enrolling every arm.
- Sponsor
- Eli Lilly and Company
- Estimated enrollment
- 4,500
- Listed locations
- 563
- Countries
- 34
- Primary completion
- August 2030
- Registry updated
- 2026-07-17
LY3437943 versus placebo in participants with obesity or overweight
A China-based study sponsored by Hudson Biotech. Its registry record uses LY3437943, but it is not an Eli Lilly-sponsored TRIUMPH trial.
- Sponsor
- Hudson Biotech
- Estimated enrollment
- 300
- Listed locations
- 1
- Countries
- 1
- Primary completion
- March 2027
- Registry updated
- 2026-03-12
Where the largest recruiting record lists locations.
SYNERGY-Outcomes is a multiple-agent MASLD master protocol. These are registry location counts, not open retatrutide slots or arm assignments.
34 states contain at least one site currently marked Recruiting.
A state name means at least one individual registry location currently carries a Recruiting site status. It does not establish an open appointment, eligibility, or assignment to a retatrutide arm.
Active does not mean recruiting.
These studies can still be treating participants, collecting outcomes, or completing follow-up. Their overall status explicitly says they are not recruiting.
| Study | Phase | Enrollment | Locations | Primary completion | Live record |
|---|---|---|---|---|---|
| NCT07035093Retatrutide in participants with obesity or overweight and chronic low back pain | Phase 3 | 586 | 40 across 4 countries | September 2027 | Verify ↗ |
| NCT05882045Retatrutide in participants with obesity and cardiovascular disease | Phase 3 | 1,946 | 169 across 10 countries | April 2026 | Verify ↗ |
| NCT05929079TRIUMPH-2 in participants with type 2 diabetes who have obesity or overweight | Phase 3 | 1,000 | 98 across 8 countries | May 2026 | Verify ↗ |
| NCT06260722TRANSCEND-T2D-2, retatrutide compared with semaglutide in type 2 diabetes | Phase 3 | 1,250 | 77 across 5 countries | August 2026 | Verify ↗ |
| NCT06297603TRANSCEND-T2D-3 in type 2 diabetes with moderate or severe renal impairment | Phase 3 | 320 | 76 across 7 countries | October 2026 | Verify ↗ |
| NCT06383390TRIUMPH-Outcomes cardiovascular and kidney outcomes study | Phase 3 | 10,000 | 743 across 27 countries | February 2029 | Verify ↗ |
| NCT06662383TRIUMPH-5, retatrutide compared with tirzepatide in adults with obesity | Phase 3 | 800 | 65 across 5 countries | November 2026 | Verify ↗ |
| NCT06859268Retatrutide in the maintenance of weight reduction in individuals with obesity | Phase 3 | 643 | 53 across 3 countries | April 2028 | Verify ↗ |
| NCT06982859Retatrutide effects on insulin secretion and insulin sensitivity in type 2 diabetes | Phase 1 | 95 | 1 across 1 country | December 2026 | Verify ↗ |
| NCT07232719Retatrutide in participants with obesity or overweight | Phase 3 | 250 | 31 across 2 countries | July 2027 | Verify ↗ |
| NCT07357415Retatrutide in participants without type 2 diabetes who have obesity or overweight | Phase 3 | 600 | 35 across 3 countries | October 2028 | Verify ↗ |
Use four gates, in order.
- 01
Match the exact condition
Obesity alone does not satisfy a study requiring chronic low back pain, MASLD, diabetes, renal impairment, or another defined condition.
- 02
Check overall status
Recruiting, Active not recruiting, Completed, and Available expanded access are different categories. Only the live registry record is current.
- 03
Check the specific location
A study can be Recruiting overall while a particular site is full, paused, not yet open, or assigned to a different arm within a master protocol.
- 04
Use the registry contact
The study team, not Peptide Local or an online seller, determines current site availability, screening, consent, and eligibility.
Trial locations, TRIUMPH status, and access.
Each answer uses the dated registry denominator. Recheck the live record before acting because recruitment and site details can change.
Are any retatrutide clinical trials recruiting?
Yes. The current ClinicalTrials.gov intervention-search snapshot contains two records with an overall Recruiting status. They are not interchangeable: one is a multiple-agent MASLD master protocol and one is a China-based Phase 2 study sponsored by Hudson Biotech. The separate chronic low-back-pain study changed to Active, not recruiting in the July 23 snapshot. The exact record and current site status must be checked before contacting a study team.
Where are retatrutide trials recruiting?
The two overall-recruiting records retain 564 listed locations across 34 countries. Of those, 450 individual site observations in 27 countries are currently marked Recruiting. Neither count is a count of open retatrutide slots. The largest record is the multiple-agent SYNERGY-Outcomes master protocol, and a listed site may not enroll every study arm.
Can I join TRIUMPH-1?
No new enrollment is indicated. TRIUMPH-1, NCT05929066, is Completed. Its locations and results remain useful evidence, but a completed study is not an enrollment route. Current recruiting records must be searched separately.
Is TRIUMPH-5 recruiting?
No. TRIUMPH-5, NCT06662383, is Active, not recruiting in the July 20, 2026 registry snapshot. It directly compares retatrutide with tirzepatide in adults with obesity, but the current status does not indicate new enrollment and no result is posted in this release.
Does Recruiting mean every listed trial site is open?
No. Overall study status and individual location availability are different fields. Sites can open, pause, fill, or close on different dates. Use the exact ClinicalTrials.gov record, then confirm the site and study contact information directly. Peptide Local does not collect applications or determine eligibility.
Is expanded access the same as joining a clinical trial?
No. Expanded access is treatment use outside a clinical trial for certain serious or immediately life-threatening conditions when no comparable or satisfactory option exists. A licensed physician, the sponsor, an institutional review board, and FDA have separate roles. An Available registry record is not a retail channel, general weight-loss program, or guarantee that a request will proceed.
Can I get or buy retatrutide outside a trial?
Retatrutide remains investigational and has no FDA-approved pharmacy product, commercial label, or routine prescription channel. Lilly says no one should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial. A seller page using the development name does not become clinical-trial material and does not inherit the sponsor's identity, quality, dose, or safety record.
14 open-program records, ready to inspect.
The release includes all Recruiting, Active not recruiting, and Available expanded-access records in the current 34-match snapshot. Completed studies stay in the denominator but are not duplicated as open-program rows.
Retatrutide remains investigational. An NCT number, study dose, location, or research-vial listing does not create a commercial pharmacy channel or authorize self-directed use.
Open the complete Retatrutide evidence profile →